Related Experiment Videos
Estrogen as a neuromodulator of MPTP-induced neurotoxicity: effects upon striatal dopamine release
1Department of Anatomy, Northeastern Ohio Universities, College of Medicine, Rootstown 44272-0095, USA.
Abstract:
The effects of estrogen upon MPTP-induced neurotoxicity were examined using in vitro superfusion. In Experiment 1, striatal tissue from ovariectomized rats was infused with MPP+ (10 microM), a combination of MPP+ and 17beta-estradiol (300 nM), the same dose of estradiol preceding MPP+, or no treatment infusion. The effects of these treatments on dopamine release rates during the infusion periods were determined. Infusion of MPP+ resulted in a significant increase in dopamine release as compared to the control. Estradiol added to the MPP+ infusion significantly attenuated this dopamine (DA) release, while estradiol treatment preceding the MPP+ had no effect. In Experiment 2, three different doses of estradiol (0.3, 3, or 300 nM) were infused simultaneously with the MPP+. Doses of estradiol below 300 nM did not attenuate the DA release. In Experiment 3, estradiol alone (300 nM) was infused, to determine dopamine release rate effects of the hormone itself. There was no difference between estradiol treated and non-infused control groups. These results demonstrate that the gonadal steroid hormone estradiol can modulate responses of striatal dopamine neurons to MPP+ by altering the immediate increase in dopamine release which occurs in response to this neurotoxin. These modulating effects of estradiol are dose-dependent, and represent a direct effect upon striatal neurons, most likely involving a non-genomic mechanism of action. These results implicate that hormonal modulation of nigrostriatal dopaminergic neurotoxicity may represent an important variable responsible for the sex differences which are reported in Parkinson's disease.
Insights
Estrogen, specifically 17beta-estradiol, can protect dopamine neurons from MPTP neurotoxicity by reducing dopamine release. This protective effect is dose-dependent and suggests hormonal modulation plays a role in sex differences observed in Parkinson's disease.
Area of Science:
- Neuroscience
- Endocrinology
- Neuropharmacology
Background:
- MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxin that selectively damages dopaminergic neurons, serving as a model for Parkinson's disease.
- Sex differences in Parkinson's disease prevalence and progression suggest hormonal influences, particularly estrogen, may play a protective role.
Purpose of the Study:
- To investigate the in vitro effects of 17beta-estradiol on MPTP-induced neurotoxicity in rat striatal tissue.
- To determine if estradiol modulates dopamine release in response to MPP+ (1-methyl-4-phenylpyridinium), the active metabolite of MPTP.
Main Methods:
- In vitro superfusion of striatal tissue from ovariectomized rats.
- Infusion of MPP+ alone, MPP+ with varying doses of 17beta-estradiol, or estradiol alone.
- Measurement of dopamine release rates during infusion periods.
Main Results:
- MPP+ infusion significantly increased dopamine release compared to controls.
- Simultaneous infusion of 300 nM 17beta-estradiol with MPP+ significantly attenuated this dopamine release.
- Lower doses of estradiol (0.3 and 3 nM) did not attenuate dopamine release, indicating a dose-dependent effect.
- Estradiol alone did not alter dopamine release rates.
Conclusions:
- 17beta-estradiol directly modulates striatal dopamine neuron responses to MPP+-induced neurotoxicity.
- The neuroprotective effect of estradiol is dose-dependent and likely involves a non-genomic mechanism.
- Hormonal modulation of nigrostriatal dopaminergic neurotoxicity may explain sex differences observed in Parkinson's disease.